SCHEMBL19857562

SCHEMBL19857562

Cc1cc2cccc(C(N)=O)c2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.53
BTK Q06187 6/20 0.50
PLK4 O00444 1/20 0.50
CHEK1 O14757 1/20 0.50
AURKA O14965 1/20 0.50
DAPK3 O43293 1/20 0.50
MAP4K4 O95819 1/20 0.50
CSF1R P07333 1/20 0.50
RET P07949 1/20 0.50
FGFR1 P11362 1/20 0.50
PDGFRA P16234 1/20 0.50
LTK P29376 1/20 0.50
KDR P35968 1/20 0.50
MAP2K2 P36507 1/20 0.50
FLT3 P36888 1/20 0.50
CSNK1A1 P48729 1/20 0.50
PRKX P51817 1/20 0.50
CDK5 Q00535 1/20 0.50
MAP2K1 Q02750 1/20 0.50
MST1R Q04912 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29696398 1.00 PDPK1 (0.53) PDPK1BTKPLK4CHEK1AURKA
SCHEMBL2078975 0.84 DHODH (0.58) KDM4EALDH1A1GAADHODHALOX15
SCHEMBL7014604 0.80 KDM4E (0.48) KDM4EALDH1A1DHODHHSD17B10
SCHEMBL31423274 0.79 PDPK1 (0.53) PDPK1BTKPLK4CHEK1AURKA
SCHEMBL6028389 0.79 DHODH (0.59) PDPK1BTKPLK4CHEK1DAPK3
SCHEMBL6028768 0.77 DHODH (0.55) PDPK1BTKPLK4CHEK1AURKA
SCHEMBL4666037 0.76 IKBKB (0.61) PARP1DHODHBRD4
SCHEMBL30356362 0.76 PARP1 (0.38) BTKPARP1BRD4
SCHEMBL18616883 0.75 KDM4E (0.38) FLT3KDM4EALDH1A1GAADHODH
SCHEMBL16382685 0.75 BTK (0.48) BTKPLK4CHEK1DAPK3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117015528-A Indole derivatives as kinase inhibitors GB005股份有限公司 2023-11-07 CN disclosed
CN-115867346-A Kinase inhibitors GB005股份有限公司 2023-03-28 CN disclosed
EP-4008328-A1 PRIMARY CARBOXAMIDES AS BTK INHIBITORS AbbVie Inc. (US) 2022-06-08 EP disclosed
EP-3483167-A1 PRIMARY CARBOXAMIDES AS BTK INHIBITORS AbbVie Inc. (US) 2019-05-15 EP disclosed
US-10174005-B2 Fused pyrimidines as inhibitors of p97 complex CLEAVE BIOSCIENCES, INC. (US) 2019-01-08 US disclosed
US-20180044325-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX CLEAVE BIOSCIENCES, INC. 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174005-B2 Fused pyrimidines as inhibitors of p97 complex WDR77, POP1, PSMG3 PDPK1 2426/4885BTK 3983/4885PLK4 1845/4885
US-20180044325-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX WDR77, POP1, PSMG3 PDPK1 2438/4885BTK 3984/4885PLK4 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.